The Mayak Worker Dosimetry System (MWDS-2013): Uncertainty in the Measurement of Pu Activity in a 24-Hour Urine Sample of a Typical Mayak PA Worker

Lung Cancer in the Mayak Workers Cohort: Risk Estimation and Uncertainty Analysis

The workers at the Mayak nuclear facility near Ozyorsk, Russia are a primary source of information about exposure to radiation at low-dose rates, since they were subject to protracted exposures to external gamma rays and to internal exposures from plutonium inhalation. Here we re-examine lung cancer mortality rates and assess the effects of external gamma and internal plutonium exposures using recently developed Monte Carlo dosimetry systems. Using individual lagged mean annual lung doses computed from the dose realizations, we fit excess relative risk (ERR) models to the lung cancer mortality data for the Mayak Workers Cohort using risk-modeling software. We then used the corrected-information matrix (CIM) approach to widen the confidence intervals of ERR by taking into account the uncertainty in doses represented by multiple realizations from the Monte Carlo dosimetry systems. Findings of this work revealed that there were 930 lung cancer deaths during follow-up. Plutonium lung doses (but not gamma doses) were generally higher in the new dosimetry systems than those used in the previous analysis. This led to a reduction in the risk per unit dose compared to prior estimates. The estimated ERR/Gy for external gamma-ray exposure was 0.19 (95% CI: 0.07 to 0.31) for both sexes combined, while the ERR/Gy for internal exposures based on mean plutonium doses were 3.5 (95% CI: 2.3 to 4.6) and 8.9 (95% CI: 3.4 to 14) for males and females at attained age 60. Accounting for uncertainty in dose had little effect on the confidence intervals for the ERR associated with gamma-ray exposure, but had a marked impact on confidence intervals, particularly the upper bounds, for the effect of plutonium exposure [adjusted 95% CIs: 1.5 to 8.9 for males and 2.7 to 28 for females]. In conclusion, lung cancer rates increased significantly with both external gamma-ray and internal plutonium exposures. Accounting for the effects of dose uncertainty markedly increased the width of the confidence intervals for the plutonium dose response but had little impact on the external gamma dose effect estimate. Adjusting risk estimate confidence intervals using CIM provides a solution to the important problem of dose uncertainty. This work demonstrates, for the first time, that it is possible and practical to use our recently developed CIM method to make such adjustments in a large cohort study.

The effects of chronic diseases on plutonium urinary excretion in former workers of the Mayak Production Association

The radiochemical analysis of plutonium activity in urine is the main method for indirect estimation of doses of internal exposure from plutonium incorporation in professional workers. It was previously shown that late-in-life acute diseases, particularly those that affect the liver, can promote accelerated rates of release of plutonium from the liver with enhanced excretion rates. This initial study examines the relationships of some chronic diseases on plutonium excretion as well as the terminal relative distribution of plutonium between the liver and skeleton. Fourteen cases from former workers at the Mayak Production Association (Mayak PA) who provided from 4–9 urine plutonium bioassays for plutonium, had an autopsy conducted after death, and had sufficient clinical records to document their health status were used in this study. Enhanced plutonium excretion was associated with more serious chronic diseases, including cardiovascular diseases and other diseases that involved the liver. These chronic diseases were also associated with relatively less plutonium found in the liver relative to the skeleton determined by analyses conducted after autopsy. These data further document health conditions that affect plutonium biokinetics and organ deposition and retention patterns and suggest that health status should be considered when conducting plutonium bioassays as these may alter subsequent dosimetry and risk models.

The Mayak Worker Dosimetry System (MWDS-2013): How to Reduce Hyper-Realisations to Realisations

Two important aspects in which the MWDS-2013 output (absorbed dose to organs calculated in each calendar year) differs from previous data bases (MWDS-2008 and DOSES-2005) are that they have been designed to (a) deal explicitly with uncertainties in model parameters, and (b) differentiate parameters that are considered to be shared (unknown, but having the same value for all workers) and unshared (unknown, but having different values between workers). A multiple-realisation approach is used to preserve information on the effects of shared and unshared parameters both for internal and external doses. Previously, a single realisation (a set of organ doses: one for each worker in the cohort) was calculated using the best estimates of parameter values only. In MWDS-2013, a set of 1000 realisations is produced, to reflect the uncertainty in assumed model parameters: each realisation using a different set of parameter values. Within each realisation, shared parameter values are fixed throughout the cohort, while unshared parameters are allowed to vary between workers. One problem is that because the calculation of organ dose is Bayesian, the estimate for each organ dose is not just a single value, but is itself a distribution (hyper-dose). Technically, it is the probability density of dose given the sampled set of parameter values and given the data for that worker. Thus, in our case, the realisations consist not of single doses, but distributions of doses. The term hyper-realisation is used to differentiate this from the more conventional realisation. Although the multiple hyper-realisation in principle contains all of the necessary information on parameter uncertainty, including shared and unshared parameters, in order to make preliminary epidemiological analyses tractable, and also for consistency with the external doses, it was required to convert the hyper-realisations to realisations. The aim of this paper is to discuss the different approaches that were considered to do this, and to define the method that was eventually chosen. Single spot (point) estimates of dose (for each worker) were also calculated to support the epidemiological analysis. The different methods for obtaining these and the implications are also discussed.

The Mayak Worker Dosimetry System (MWDS-2013): Internal Dosimetry Results

The distribution of calculated internal doses has been determined for 8043 Mayak Production Associate (Mayak PA) workers. This is a subset of the entire cohort of 25 757 workers, for whom monitoring data are available. Statistical characteristics of point estimates of accumulated doses to 17 different tissues and organs and the uncertainty ranges were calculated. Under the MWDS-2013 dosimetry system, the mean accumulated lung dose was 185 ± 594 mGy (geometric mean = 28 mGy; geometric standard deviation = 9.32; median value = 31 mGy; maximum value = 8980 mGy). The ranges of relative standard uncertainty were from 40 to 2200% for accumulated lung dose, from 25-90% to 2600-3000% for accumulated dose to different regions of respiratory tract, from 13-22% to 2300-2500% for systemic organs and tissues. The Mayak PA workers accumulated internal plutonium lung dose is shown to be close to log normal. The accumulated internal plutonium dose to systemic organs was close to a log triangle. The dependency of uncertainty of accumulated absorbed lung and liver doses on the dose estimates itself is also shown. The accumulated absorbed doses to lung, alveolar-interstitial region, liver, bone surface cells and red bone marrow calculated both with MWDS-2013 and MWDS-2008 have been compared. In general, the accumulated lung doses increased by a factor of 1.8 in median value, while the accumulated doses to systemic organs decreased by factor of 1.3-1.4 in median value. For the cases with identical initial data, accumulated lung doses increased by a factor of 2.1 in median value, while accumulated doses to systemic organs decreased by 8-13% in median value. For the cases with both identical initial data and all of plutonium activity in urine measurements above the decision threshold, accumulated lung doses increased by a factor of 2.7 in median value, while accumulated doses to systemic organs increased by 6-12% in median value.